Skip to content

The Effect of Evening Primrose Oil on Clinical Symptoms in Women with Polycystic Ovary Syndrome

The Effect of Evening Primrose Oil on Clinical Symptoms in Women with Polycystic Ovary Syndrome: A Randomized Controlled Trial

Status
Recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20120718010324N73
Enrollment
62
Registered
2022-11-08
Start date
2022-10-21
Completion date
Unknown
Last updated
2022-11-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Polycystic Ovary Syndrome (PCOS). Polycystic ovarian syndrome

Interventions

Intervention 1: Intervention group: For each person three matte container including 30 1000 mg evening primrose oil capsules will be prepared with a certain number. At the beginning of the study, a co

Sponsors

Tabriz University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
18 Years to 45 Years

Inclusion criteria

Inclusion criteria: Confirmation of the diagnosis of PCOS according to the criteria of the Androgen Excess/PCOS Society, including anovulation, chronic low ovulation, or polycystic ovaries and clinical or biochemical signs of hyperandrogenism Minimum hirsutism score of 6 with the Freeman Galloway criterion Having literacy to complete the questionnaires BMI between 18.5 and 40 Ages 18-45 years Not taking vitamins, minerals and omega-6 in the three months before the intervention

Exclusion criteria

Exclusion criteria: Having other androgenic disorders such as adrenal hyperplasia or androgen-producing tumor Having Cushing's syndrome Having thyroid gland diseases Pregnancy or breastfeeding Women undergoing infertility treatment at the time of the study Previous surgery on one or both ovaries Consumption of dietary supplements Smoking and alcohol consumption Occurrence of unfortunate events

Design outcomes

Primary

MeasureTime frame
Hirsutism score. Timepoint: Before the intervention and after the end of intervention. Method of measurement: Ferriman – Gallwey index.;Depression symptoms score. Timepoint: Before the intervention and after the end of intervention. Method of measurement: Beck Depression Inventory.

Secondary

MeasureTime frame
Frequency of adverse events in the study groups. Timepoint: During the intervention. Method of measurement: Researcher-made checklist.;Anthropometric indices (waist circumference, hip circumference, BMI). Timepoint: Before and after the intervention. Method of measurement: Checklist of anthropometric indices.;Menstrual disorders. Timepoint: Before and after the intervention. Method of measurement: Menstrual characteristics questionnaire.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatemeh Nouranfar

Tabriz University of Medical Sciences

fateme96nour@gmail.com+98 41 3523 0741

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026